Human Liver Kept Alive Outside the Body for 7 Weeks: The Record Comes First, The Answers Are Yet to Follow
A Sydney-based team used automated perfusion to keep a donated human liver functional ex vivo for seven weeks, breaking the previous world record. But the record itself does not guarantee the organ's quality, and the real core question is what applications long-term perfusion can deliver for preserved organs.
A transplant team in Sydney connected a donated human liver to a set of automated pumps and sensors, keeping it functional outside the human body for seven weeks. The team dubs this system an "artificial body", with its official name being the Extended Organ Perfusion System. The procedure was led by Carlo Pulitano, a transplant surgeon at Royal Alfred Hospital and professor at the University of Sydney. The findings have not been formally published yet.
The key to the breakthrough lies in full automation. Earlier this year, Pulitano's team presented their trial of continuous perfusion on 55 human livers at the ILTS Congress in Switzerland. Manual perfusion systems require constant, frequent adjustments, while the automated system raised the average liver survival time to around four weeks — three times that of the manual group. The 7-week surviving liver was maintained with this automated system, kept at a steady temperature of roughly 37°C. Prior to this, the world record for ex vivo human liver survival was held by a Swiss team, at around two weeks.
Traditionally, organs slated for transplant can only last for a few hours in an ice cooler, forcing medical teams to rush them to recipients as fast as possible. Over the past decade, perfusion systems have gradually entered clinical use: they deliver nutrients and blood to organs and remove waste via warm or cooled fluids, effectively doubling the maximum organ preservation window. Perfusion technology has already allowed doctors to restart hearts from deceased donors and keep them beating outside the human body. Paulo Martins, a transplant surgeon at the University of Oklahoma, notes that roughly half of the kidneys he transplants go through perfusion, though the procedure can add up to $100,000 in costs per transplant.
The new 7-week record is clearly newsworthy, but its actual medical value remains to be verified. Waldemar Hoffmann, CEO and co-founder of Apersys, says the industry broadly believes Pulitano's record is legitimate, but no one knows how healthy the 7-week liver ultimately was, nor what concrete use the extra preservation time can serve. He asks: "What is the actual point of perfusing a liver for seven weeks?" This is an unpopular question, but one that must be answered: the record has arrived first, but the answers are nowhere to be seen yet.
The scope of possible applications for long-term ex vivo perfusion is expanding rapidly. Researchers have found that organs may show signs of repair roughly one day after being placed in perfusion, with damaged organs regaining function and getting stronger. In 2022, a Swiss team transplanted a damaged liver that had been perfused for three days, publishing their findings in Nature Biotechnology. Pulitano's startup Aeternum Life Technologies will participate in a trial program in Sydney that transplants low-quality livers after four days of perfusion.
More far-reaching visions for the technology include artificial wombs, lab-grown organ manufacturing, and running long-term experiments on intact human organs outside the body. In living donor liver transplants, surgeons often remove half of a donor's liver, and within roughly two months, both halves regenerate to close to their original full volume. Pulitano has experimented with splitting livers and connecting the segments to the perfusion machine: if the method works, one donated liver could potentially be turned into multiple full-sized transplantable organs. US biotech firm Bexorg uses perfusion pumps to "resuscitate" human brains for experimental drug research, currently keeping the brains functional for about one day, with a target of reaching two weeks. Pulitano has also administered gene therapy to ex vivo perfused livers. He puts it plainly: this technology provides a living human organ model that no animal model can replace, since the biology, immunology and drug response profiles are inherently human from the start. A patent from Altos Labs describes introducing reprogramming genes into ex vivo animal livers, and even envisions temporarily disconnecting a failing organ inside a human patient, hooking it up to a perfusion machine to deliver intensive gene therapy.
The field is also becoming more organized. Martins founded the International Society for Organ Preservation and Perfusion Therapy, which held its inaugural conference in Italy earlier this year. In China, a relevant professional society was launched in August this year, and the team from the First Affiliated Hospital of Sun Yat-sen University proposed the concept of Organ Medicine, centered on the core idea of "bionic maintenance". As Pulitano notes, what is truly exploding right now is this technology that clearly goes far beyond the original concept of simple organ preservation.
Back to the 7-week liver milestone: it proves that an automated life support system can keep a human liver functional outside the body for lengths of time that were unthinkable in the past. It also proves that extended organ survival immediately brings up a whole new set of follow-up questions: around organ quality, cost, ethics, trial design, and most importantly, what exact clinical scenario requires keeping a liver outside a human body for nearly two months. Technical records easily make headlines, but the actionable medical answers almost always lag behind.
发布时间: 2026-11-19 20:00